Technical Briefing: Accuray, Antares Pharma, Chelsea Therapeutics, and Anthera Pharma

Technical Briefing: Accuray, Antares Pharma, Chelsea Therapeutics, and Anthera
                                    Pharma

PR Newswire

LONDON, July 26, 2013

LONDON, July 26, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.



The U.S. equity market managed to post gains on Thursday, July 25, 2013. Both
Dow Jones and the S&P 500 remained in red for most part of the day. However, a
recovery in late trading hours helped the indices to end higher. Shares in the
healthcare sector ended on a mixed note even as the broader market edged
higher. The major movers in the sector included Accuray Incorporated (NASDAQ:
ARAY), Antares Pharma Inc. (NASDAQ: ATRS), Chelsea Therapeutics International
Ltd. (NASDAQ: CHTP), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). All
these companies are tracked by AAAResearchReports.com. Free technical research
reports on ARAY, ATRS, CHTP, and ANTH can be accessed by signing up at:

http://www.aaaresearchreports.com/register/ 

Shares in Accuray Inc. moved higher on Thursday, tracking gains in the broader
market. The company's shares ended the day 1.48% higher at $6.18 after
fluctuating between $6.01 and $6.24. A total of 1.65 million shares were
traded which is more than the daily average volume of 883,060. Accuray's
shares have gained 1.64% in the last three trading sessions and 13.60% in the
last one month, thus outperforming the S&P 500. Moreover, the stock is
currently trading above its 50-day and 200-day moving averages. Download free
report on ARAY upon registration at:

http://www.AAAResearchReports.com/ARAY072613.pdf

Antares Pharma Inc.'s stock rallied on Thursday, reversing all of its losses
from previous trading sessions. The company's shares ended the day 4.96%
higher at $4.44 after oscillating between $4.19 and $4.48. A total of 857,902
shares were traded which is below the daily average volume of 946,051. Antares
Pharma's shares have advanced by 0.91% in the last three trading sessions,
thus outperforming the S&P 500. Furthermore, the stock is currently trading
above its 50-day and 200-day moving averages. ATRS technical report can be
accessed for free by signing up at:

http://www.AAAResearchReports.com/ATRS072613.pdf

Shares in Chelsea Therapeutics International Ltd fell sharply on Thursday,
extending their losses from previous trading sessions. The company's shares
fluctuated between $3.01 and $3.15 before finishing the day 1.59% lower at
$3.09. A total of 1.20 million shares were traded which is below the daily
average volume of 1.35 million. Chelsea Therapeutics International's shares
have fallen by 3.13% in the last three trading sessions. Despite the recent
pullback, the stock is currently trading near its 52-week high of $3.25. A
free report on CHTP can be accessed by registering at:

http://www.AAAResearchReports.com/CHTP072613.pdf

Anthera Pharmaceuticals Inc.'s stock slipped on Thursday even as the broader
market edged higher. The company's shares oscillated between $4.19 and $4.30
before finishing the day 1.62% lower at $4.26. A total of 66,862 shares were
traded which is below the daily average volume of 120,522. The company's
shares have dropped by 2.74% in the last three trading sessions, and 8.74% in
the last three months, underperforming the S&P 500. Register with AAA Research
Reports and download research on ANTH for free at:

http://www.AAAResearchReports.com/ANTH072613.pdf

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE AAA Research Reports

Contact: AAAresearchreports.com Phone #: + 1 (646) 396-9126
 
Press spacebar to pause and continue. Press esc to stop.